The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Open accessAbstract
Purpose: Improvement of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT) will require efforts to decrease treatment-related mortality from severe viral infections. Adoptively transferred virus-specific T cells (VSTs) generated from eligible, third-party donors could provide broad antiviral protection to recipients of HSCT as an immediately available off-the-shelf product. Patient and Methods: We generated a bank of VSTs that recognized five common viral pathogens: Epstein-Barr virus (EBV), adenovirus (AdV), cytomegalovirus (CMV), BK virus (BKV), and human herpesvirus 6 (HHV-6). The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. Results: A single infusion produced a cumulative complete or partial response rate of 92% (95% CI, 78.1% to 98.3%) overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (n = 3). Clinical benefit was achieved in 31 patients treated for one infection and in seven patients treated for multiple coincident infections. Thirteen of 14 patients treated for BKV-associated hemorrhagic cystitis experienced complete resolution of gross hematuria by week 6. Infusions were safe, and only two occurrences of de novo graft-versus host disease (grade 1) were observed. VST tracking by epitope profiling revealed persistence of functional VSTs of third-party origin for up to 12 weeks. Conclusion: The use of banked VSTs is a feasible, safe, and effective approach to treat severe and drug-refractory infections after HSCT, including infections from two viruses (BKV and HHV-6) that had never been targeted previously with an off-the-shelf product. Furthermore, the multispecificity of the VSTs ensures extensive antiviral coverage, which facilitates the treatment of patients with multiple infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Self-citationCellular responses to viral infection in humans: lessons from Epstein–Barr virus
Hislop, A. D., Taylor, G. S., Sauce, D., & Rickinson, A. B. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141553 · Cited by 766
Einsele, H., Roosnek, E., Rufer, N., Sinzger, C., Riegler, S., Löffler, J., Grigoleit, U., Moris, A., Rammensee, H.-G., Kanz, L., et al. (2002) · Blood · doi:10.1182/blood.v99.11.3916 · Cited by 699
Leen, A. M., Bollard, C. M., Mendizabal, A. M., Shpall, E. J., Szabolcs, P., Antin, J. H., Kapoor, N., Pai, S.-Y., Rowley, S. D., Kebriaei, P., et al. (2013) · Blood · doi:10.1182/blood-2013-02-486324 · Cited by 553
Self-citationLeen, A. M., Myers, G. D., Sili, U., Huls, M. H., Weiss, H., Leung, K. S., Carrum, G., Krance, R. A., Chang, C.-C., Molldrem, J. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1475 · Cited by 545
Self-citationPeggs, K. S., Verfuerth, S., Pizzey, A., Khan, N., Guiver, M., Moss, P. A., & Mackinnon, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14634-x · Cited by 462
Doubrovina, E., Oflaz-Sozmen, B., Prockop, S. E., Kernan, N. A., Abramson, S., Teruya-Feldstein, J., Hedvat, C., Chou, J. F., Heller, G., Barker, J. N., et al. (2012) · Blood · doi:10.1182/blood-2011-08-371971 · Cited by 421
Papadopoulou, A., Gerdemann, U., Katari, U. L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A. P., Vera, J. F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008825 · Cited by 402
Self-citationBroers, A. E. C., van der Holt, R., van Esser, J. W. J., Gratama, J.-W., Henzen-Logmans, S., Kuenen-Boumeester, V., Löwenberg, B., & Cornelissen, J. J. (2000) · Blood · doi:10.1182/blood.v95.7.2240 · Cited by 348
Gratwohl, A., Brand, R., Frassoni, F., Rocha, V, Niederwieser, D., Reusser, P., Einsele, H., Cordonnier, C., & for the Acute and Chronic Leukemia Working Parties and the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705140 · Cited by 292
Cited by
Razonable, R. R., & Humar, A. (2019) · Clinical Transplantation · doi:10.1111/ctr.13512 · Cited by 753
Induced pluripotent stem cells in disease modelling and drug discovery
Rowe, R. G., & Daley, G. Q. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0100-z · Cited by 670
Velleca, A., Shullo, M. A., Dhital, K., Azeka, E., Colvin, M., DePasquale, E., Farrero, M., García-Guereta, L., Jamero, G., Khush, K., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.015 · Cited by 645
Farrell, P. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 541
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N., Hamieh, M., Hegde, M., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 303
Tyler, K. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1708714 · Cited by 275
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells
Kumaresan, P. R., da Silva, T. A., & Kontoyiannis, D. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01939 · Cited by 85
“A precedent for this approach was reported, in which third-party Epstein–Barr virus-specific T cells and multivirus-specific T cells were infused (119, 176, 177).”
BackgroundResultImmunomodulation as Therapy for Fungal Infection: Are We Closer?
Sam, Q. H., Yew, W. S., Seneviratne, C. J., Chang, M. W., & Chai, L. Y. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01612 · Cited by 68
Eliassen, E., Hemond, C. C., & Santoro, J. D. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.10.004 · Cited by 37
Immunomodulation as a Therapy for Aspergillus Infection: Current Status and Future Perspectives
Lauruschkat, C. D., Einsele, H., & Loeffler, J. (2018) · Journal of Fungi · doi:10.3390/jof4040137 · Cited by 32
Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s
DeRenzo, C., & Gottschalk, S. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43032-0_10 · Cited by 12
Self-citation
Metadata
- Authors
- Tzannou, I., Papadopoulou, A., Naik, S., Leung, K., Martinez, C. A., Ramos, C. A., Carrum, G., Sasa, G., Lulla, P., Watanabe, A., Kuvalekar, M., Gee, A. P., Wu, M.-F., Liu, H., Grilley, B. J., Krance, R. A., Gottschalk, S., Brenner, M. K., Rooney, C. M., Heslop, H. E., Leen, A. M., & Omer, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-11-01
- Volume
- 35
- Issue
- 31
- Pages
- 3547-3557
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2744246163
- Cited by
- 457
- References
- 32
- FWCI
- 31.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.